替罗非班联合双抗治疗对致残性缺血性小卒中患者的影响  

Effect of tirofiban combined with dual-antibody therapy on patients with disabling minor ischemic stroke

作　　者：朱网明 田荣华 崔春霞 Zhu Wang-ming;Tian Rong-hua;Cui Chun-xia(Department of Emergency,Haian People's Hospital,Haian 226600,China;Department of General Medical Practice,Haian People's Hospital,Haian 226600,China)

机构地区：[1]海安市人民医院急诊科,海安226600 [2]海安市人民医院全科医疗科,海安226600

出　　处：《中国药物应用与监测》2024年第4期407-411,共5页Chinese Journal of Drug Application and Monitoring

摘　　要：目的 探讨替罗非班联合双抗治疗对致残性缺血性小卒中患者不良心脑血管事件及复发情况的影响。方法 选取2021年3月至2023年6月海安市人民医院收治的缺血性小卒中患者154例,根据是否使用替罗非班分为观察与对照组,各77例,对照组采用常规抗血小板治疗,观察组在对照组的基础上加用替罗非班。对比分析两组的临床疗效、治疗前后美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(m RS)、血小板参数变化、不良心脑血管事件及复发情况。结果 观察组治疗总有效率[92.20%(71/77)]与对照组[83.16%(64/77)]对比差异无统计学意义(χ^(2)=2.942,P>0.05)。在NIHSS、m RS评分方面,治疗后两组患者全部出现下降情况,观察组[分别为(1.13±0.19)分,(1.30±0.33)分]相较于对照组[分别为(1.36±0.21)分,(1.62±0.35)分]更低(t=7.126、5.837,均P<0.05)。观察组治疗后的MPV、PDW[分别为(9.15±1.26) fl、(12.14±1.63)%]低于对照组[分别为(11.03±1.35) fl、(13.28±1.67)%],PCT[(0.35±0.06)%]高于对照组[(0.28±0.04)%](t=8.933、4.286、8.518,均P<0.05)。观察组的不良心脑血管事件发生率、复发率[分别为6.49%(5/77)、3.89%(3/77)]与对照组[分别为12.98%(10/77)、7.79%(6/77)]比较差异无统计学意义(χ^(2)=1.847、0.472,均P>0.05)。结论 替罗非班联合双抗治疗可有效改善致残性缺血性小卒中患者的神经功能、血小板功能,改善患者的预后,且不会增加不良心脑血管事件发生风险。Objective To investigate the effect of tirofiban combined with dual-antibody therapy on adverse cardiovascular and cerebrovascular events and recurrence in patients with disabling minor ischemic stroke.Methods The clinical data of 154 patients with disabling minor ischemic stroke admitted to Haian People's Hospital from March 2021 to June 2023 were retrospectively analyzed.The patients were divided into two groups according to different treatment approaches,with 77 in each group.The patients in the control group were given conventional antiplatelet therapy while those in the observation group underwent tirofiban adjuvant therapy based on the treatment regimen in the control group.Then the clinical efficacy,National Institutes of Health stroke scale(NIHSS),Modified Rankin Scale(mRS),changes in platelet parameters,adverse cardiovascular and cerebrovascular events and recurrence were compared between the two groups.Results There was no statistically significant difference in the treatment effective rate between the observation group(92.20%(71/77))and the control(83.16%(64/77))(χ^(2)=2.942,P>0.05).In terms of NIHSS and mRS scores,all patients in the two groups showed a decrease after treatment,and they were lower in the observation group than in the control((1.13±0.19)points vs(1.36±0.21)points,(1.30±0.33)points vs(1.62±0.35)points,t=7.126,5.837,both P<0.05).The observation group had smaller mean platelet volume(MPV)and platelet distribution width(PDW)and larger plateletcrit(PCT)as compared with the control((9.15±1.26)fl vs(11.03±1.35)fl,(12.14±1.63)%vs(13.28±1.67)%,(0.35±0.06)%vs(0.28±0.04)%,t=8.933,4.286,8.518,all P<0.05).The adverse cardiovascular and cerebrovascular event rate and recurrence rate of the observation group were 6.49%(5/77)and 3.89%(3/77)but those of the control were 12.98%(10/77)and 7.79%(6/77),showing no statistical difference between the two groups(χ^(2)=1.847,0.472,both P>0.05).Conclusion Application of tirofiban combined with dual-antibody therapy in patients with disabling minor is

关 键 词：致残性缺血性小卒中 替罗非班 不良心脑血管事件 复发 神经功能 血小板功能 

分 类 号：R743.3[医药卫生—神经病学与精神病学]